The stock of Galera Therapeutics Inc. (NASDAQ:GRTX) decreased by $0.0 on Friday to finish at $0.22, up 0.74 percent. The last five days have seen an average of 2,196,840 shares of common stock traded. 15 times new highs were reached in the current year, with a fall of -$1.2724. The average number of shares traded over the last 20 days was 5,915,715, while the average volume over the last 50 days totaled 2,870,180.
GRTX stock dropped -90.82% since last month. On 08/22/23, the company’s shares reached a one-month low of $0.2100. The stock touched a high of $3.59 on 06/13/23, after rallying from a low of $0.21 in 52 weeks. The price of GRTX stock has declined by -85.40% or -$1.2724 this year, reaching a new high 15 times. Still, the stock price is down -93.94% from the 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Insider Transactions
GRTX stock investors should be aware that Galera Therapeutics Inc. (GRTX) stock had its last reported insider trading activity 165 days ago on Mar 16. On Mar 16, Chief Commercial Officer Bachleda Mark acquired 11,000 shares at $2.25 each. This transaction resulted in the insider spending $24,717. On Mar 13, Degnan Chris added 10,000 shares at a price of US$1.96. After the transaction, the insider now owns 10,000 shares. President and CEO Sorensen Mel had earlier bought 100,000 shares on Mar 10 for $1.68 a share. The transaction was completed for $168,120.
Financial Health
For the three months ended June 29, Galera Therapeutics Inc.’s quick ratio was 3.10, while its current ratio was 3.10, indicating its ability to pay off its debt. Based on annual data, it had gross profit of $11.57 million and revenue of $51.23 million.
Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. GRTX’s return on assets (ROA) during the last 12 months has been -139.40%. In the meantime, the return on equity (ROE) for the last 12 months was 67.40%.
Earnings Surprise
According to Galera Therapeutics Inc.’s quarterly financial report for the quarter that ended June 29. A higher net income was reported in the quarter under review than the previous quarter. It was predicted that Galera Therapeutics Inc.’s quarterly earnings would be -$0.48, but it ended up being -$0.38, beating the consensus by -26.30%. EBITDA was -$16.8 million for the quarter. At the end of Galera Therapeutics Inc.’s most recent quarter ended June 29, its liabilities totaled 163.28 million, while its total debt was $149.58 million. Equity owned by shareholders amounts to $43.93 million.
Technical Picture
Here’s a quick look at Galera Therapeutics Inc.’s (GRTX) price momentum from a technical perspective. As of 25 August, the RSI 9-day stood at 12.08%, suggesting the stock is oversold, with a 59.35% historical volatility rate.
The stochastic %K and %D were 0.27% and 0.26% respectively, while the average true range (ATR) was 0.1258. Based on the 14-day stochastic reading of 0.36%, the RSI (14) reading is 15.82%. On the 9-day MACD Oscillator, the stock is at -0.0132, and the 14-day reading is at -0.3123.
Analyst Ratings
Galera Therapeutics Inc. (NASDAQ: GRTX) was downgraded by Piper Sandler to a a Neutral rating in its latest research report. The stock was previously rated as a an Overweight. Analysts have assigned Galera Therapeutics Inc. (GRTX) an Hold rating. GRTX is a stock that is recommended for selling by 0 brokerage firms, while 3 companies recommend holding. The stock is underweighted by 0 analysts. Among the analysts who rate the stock, 0 rates it overweight and 0 others recommend it as a buy.
What is GRTX’s price target for the next 12 months?
The current consensus forecast for the stock is between $0.30 and $0.50, with a median target price of $0.40. In analyzing these forecasts, the average price target given by analysts for Galera Therapeutics Inc. (GRTX) is $0.40.
